Dofetilide and Sodium Polystyrene Sulfonate Suspension
Determining the interaction of Dofetilide and Sodium Polystyrene Sulfonate Suspension and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using dofetilide together with sodium polystyrene sulfonate can increase the risk of an irregular heart rhythm that may be serious. If your doctor prescribes these medications together, you may need regular monitoring of your electrolyte (magnesium, potassium) levels as well as other tests to safely use both medications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, or fast or pounding heartbeats during treatment with dofetilide. In addition, you should let your doctor know if you experience signs of electrolyte disturbance such as weakness, tiredness, drowsiness, confusion, muscle pain, cramps, dizziness, nausea, or vomiting. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR CLOSELY: Dofetilide can cause dose- and concentration-related QT interval prolongation. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential.
MANAGEMENT: Caution is advised if dofetilide must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with dofetilide. During therapy, potassium concentrations should be kept above 4 mEq/dL and magnesium concentrations above 1.8 mg/dL. Patients should also have frequent ECGs and be monitored for serious arrhythmias when QT intervals are prolonged. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.
- "Product Information. Tikosyn (dofetilide)" Pfizer US Pharmaceuticals, Atlanta, GA.
Generic Name: sodium polystyrene sulfonate
Brand name: Kalexate, Kayexalate, Kionex
Synonyms: Sodium polystyrene sulfonate, Sodium Polystyrene Sulfonate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dofetilide-Sodium Sulf/Potassium Sulf/Mag Sulf/Polyethylene Glycol-Electrolyte Soln
- Dofetilide-Sodium Sulfacetamide and Sulfur Aqueous Gel
- Dofetilide-Sodium Sulfacetamide and Sulfur Cleanser
- Dofetilide-Sodium Sulfacetamide and Sulfur Cream
- Dofetilide-Sodium Sulfacetamide and Sulfur Foam
- Dofetilide-Sodium Sulfacetamide and Sulfur Lotion
- Sodium Polystyrene Sulfonate Suspension-DOK
- Sodium Polystyrene Sulfonate Suspension-Dok Plus
- Sodium Polystyrene Sulfonate Suspension-Dolasetron
- Sodium Polystyrene Sulfonate Suspension-Dolasetron Injection
- Sodium Polystyrene Sulfonate Suspension-Dolasetron Mesylate
- Sodium Polystyrene Sulfonate Suspension-Dolasetron Oral, Intravenous